Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB), TScan Therapeutics (TCRX) and Teladoc (TDOC)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Upstream Bio, Inc. (UPB – Research Report), TScan Therapeutics (TCRX – Research Report) and Teladoc (TDOC – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Upstream Bio, Inc. (UPB)
TD Cowen analyst Yaron Werber maintained a Buy rating on Upstream Bio, Inc. yesterday. The company’s shares closed last Wednesday at $9.36, close to its 52-week low of $6.63.
According to TipRanks.com, Werber is a 5-star analyst with an average return of
Upstream Bio, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $52.25, representing a 540.3% upside. In a report issued on March 2, William Blair also maintained a Buy rating on the stock.
See today’s best-performing stocks on TipRanks >>
TScan Therapeutics (TCRX)
In a report released yesterday, Maxwell Skor from Morgan Stanley maintained a Hold rating on TScan Therapeutics. The company’s shares closed last Wednesday at $1.15.
According to TipRanks.com, Skor is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for TScan Therapeutics with a $6.00 average price target, which is a 417.2% upside from current levels. In a report issued on March 4, TipRanks – xAI also reiterated a Hold rating on the stock with a $1.00 price target.
Teladoc (TDOC)
Truist Financial analyst Jailendra Singh reiterated a Hold rating on Teladoc today. The company’s shares closed last Wednesday at $5.47.
According to TipRanks.com, Singh has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Teladoc has an analyst consensus of Moderate Buy, with a price target consensus of $7.22, representing a 30.3% upside. In a report issued on February 25, William Blair also maintained a Hold rating on the stock.
